Form 6-K Innate Pharma SA For: Aug 10
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: August 10, 2026
Commission File Number: 001-39084
Innate Pharma S.A.
(Translation of registrant's name into English)
Innate Pharma S.A.
117 Avenue de Luminy—BP 30191
13009 Marseille, France
+ 33 (0) 4 30 30 30
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ]
INCORPORATION BY REFERENCE
This Report on Form 6-K, Exhibit 99.1 (other than the quote from Jonathan Dickinson, CEO of Innate Pharma S.A., the quote from Guido Oelkers, President and CEO of Sobi, the text “About Sobi” and the related hyperlinks, and the Company contact details and hyperlinks for additional information) and Exhibit 99.2 (other than the quote from Dr. Sonia Quaratino, former Chief Medical Officer of Innate Pharma S.A., the quote from Dr. Markus Jensen, the incoming Chief Medical Officer of Innate Pharma S.A., the quote from Jonathan Dickinson, CEO of Innate Pharma S.A., the text “About Sobi” and the related hyperlinks, and the Company contact details and hyperlinks for additional information) shall be deemed to be incorporated by reference into the registration statement on Form F-3 (File No. 333-276164) and registration statement on Form S-8 (File No. 333 282031) of Innate Pharma S.A. (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
Exhibit Description
99.1 Press Release dated August 10, 2026: Innate Pharma Enters Strategic Partnership with Sobi to License Lacutamab in T-Cell Lymphoma
99.2 Press Release dated August 10, 2026: Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership with Sobi and Appoints New Chief Medical Officer
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
INNATE PHARMA S.A.
Date: August 10, 2026 By: /s/ JONATHAN DICKINSON Name: Jonathan Dickinson
Title: Chief Executive Officer
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Innate Pharma S.A. (IPHA) PT Raised to $7 at H.C. Wainwright
- Sobi licenses lacutamab from Innate Pharma in $75M upfront deal
- eSUN Unveils PLA-HF: The Ultra-High-Speed 3D Printing Filament Breaking the 1000mm/s Barrier
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
